Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC

　　Tabrecta(Capmatinib):Precision Medicine for METex14-Mutated NSCLC

　　Tabrecta(Capmatinib)is an oral,prescription medication approved for adults with locally advanced or metastatic non-small cell lung cancer(NSCLC)harboring a MET exon 14 skipping mutation(METex14).As a highly selective MET tyrosine kinase inhibitor,it offers a targeted treatment option supported by compelling clinical data.

　　Administration Guidelines:

　　●Confirm METex14 mutation through genetic testing.

　　●Take 400mg orally twice daily;continue until disease progression or unacceptable toxicity.

　　●Dose adjustments(reduction or interruption)may be required based on adverse events.

　　Mechanism of Action:Halting Cancer Cell Proliferation

　　In METex14-mutated NSCLC,aberrant MET protein drives uncontrolled cell growth.Capmatinib selectively blocks MET kinase activity,disrupting oncogenic signaling pathways and suppressing tumor proliferation and metastasis.

　　Clinical Efficacy Highlights:

　　●In a pivotal study,44%of patients achieved partial or complete tumor shrinkage.

　　●Median duration of response exceeded 10 months,indicating durable disease control.

　　●Data from single-arm trials;no head-to-head comparisons with other therapies.

　　Safety Profile and Management:

　　●Common side effects(≥20%):Peripheral edema,nausea,vomiting,fatigue,dyspnea,decreased appetite.

　　●Serious adverse events include interstitial lung disease,hepatotoxicity,pneumonia;require vigilant monitoring.

　　●Promptly report symptoms to healthcare providers for personalized management.

　　Key Considerations:

　　Tabrecta is a targeted therapy prescribed by oncologists.Regular assessments ensure therapeutic benefit outweighs risks.